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To the editor.  
Next-generation sequencing (NGS) has opened the 
opportunity for assessing the unique clonal composition 
of patients with acute myeloid leukemia (AML), not 
only at the beginning but also within the course of the 
disease, and particularly at relapse. The molecular 
genetic characterization of the clonal composition has 
therapeutic relevance, as a number of molecularly 
directed treatment options have recently become 
available. Since relapse of AML remains a major 
clinical challenge, comprehensive diagnostics during 
follow-up and at relapse has become an increasingly 
important pillar of clinical decision making. In the 
current manuscript, we have applied myeloid NGS panel 
sequencing to compare the genetic profiles of six 
illustrative AML patients at initial diagnosis and at 
relapse. We found that NGS has the potential to identify 
clonal molecular stability, evolution, and devolution in 
addition to co-occurring changes on the cytogenetic 
level, all of which can occur alone or in combination. 
We discuss these patients in detail, covering clinical, 
molecular, and cytogenetic, as well as therapeutic 
aspects.  
The increasing use of NGS has been enabled by a 
number of commercially available panels that cover the 
most frequently mutated genes. In contrast to traditional 
diagnostic tools (i.e., cytomorphology, cytogenetics, 
qPCR) that provide classification and prognostic 
information only within certain categories, molecular 
profiling by NGS enables us to depict a unique genetic 
make-up for each AML patient. Genetic information 
provides crucial parameters within the current AML 
classification systems1,2 and has not only an impact on 
prognosis but also influences treatment options.  
However, despite improving remission rates, around 
40-60% of AML patients will ultimately relapse3, which 
remains the major determinant of outcome. At relapse, 
AML patients can either present with the same genetic 
mutation pattern as observed at initial diagnosis (clonal 
stability), or present with higher complexity, e.g., 
through the acquisition of additional mutations (clonal 
evolution), or lose some of the initial mutations at 
relapse (clonal devolution), or, alternatively, show both 
gains and losses of mutations.4-6  
Concerning the pathophysiologic mechanisms 
involved during clonal evolution at relapse, our current 
paradigms suggest that pre-existing clones (or 
subclones) may gain a survival advantage under the 
selective chemotherapeutic pressure.6 We have recently 
provided a comprehensive overview of the current 
knowledge of NGS during relapse of AML.7 Here, we 
present six illustrative patient studies observed during 
clinical practice to demonstrate characteristic genetic 
scenarios accompanying hematologic relapse of AML 
following intensive chemotherapy. All patients were 
treated and analyzed by cytogenetics and myeloid NGS 
panels at diagnosis and at relapse at our department 
according to the methodology described in Table 1. The 
sensitivity of NGS analyses was limited to a 5% variant 
allele frequency (VAF) at diagnosis, and 1% at follow-
up as the exact mutation localizations were known. 
 
Patient #1: Molecular and cytogenetic stability at 
relapse after intensive chemotherapy. A 51-year-old 
male patient presented with de novo AML, FAB M1, 46, 
XY, and bone marrow (BM) blasts >90%. Fragment 
analysis revealed an FLT3-ITD with a mutant/wild-type 
ratio of >0.5, and PCR detected an NPM1 (type B) 
mutation. No additional mutations were detected by 
NGS. Standard induction chemotherapy (cytarabine/ 
idarubicin followed by cytarabine/daunorubicin) 
induced complete morphologic remission (CR) with 
minimal/measurable residual disease (MRD) positivity 
according to HOVON-132 for the previously known 
NPM1 mutation. After high-dose chemotherapy 
(HDCT) with busulfan/cyclophosphamide and 
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Table 1: Examples of six AML patients relapsing after intensive chemotherapy; NGS is performed at diagnosis and relapse.   
Patient # 
age, sex 
AML 
subtype Genetic profile at initial AML diagnosis Genetic profile at relapse 
#1: Molecular and cytogenetic stability at relapse after intensive chemotherapy 
51; M† de novo, FAB M1 
46,XY[20]; 
FLT3-ITD ((ratio (mut/wt) >0.5%));  
NPM1 (type B) [c.863_864insCATG, 
p.Trp288Cysfs*12]. 
46,XY[20]; 
FLT3-ITD (ratio (mut/wt) <0.5%);  
NPM1 (type B) [c.863_864insCATG, 
p.Trp288Cysfs*12; VAF: 51%]. 
#2: Molecular and cytogenetic stability at relapse after allogeneic transplant 
63; M†† 
sAML 
(post 
MDS) 
46,XY[20]; 
ASXL1 [c.1934dup, p.Gly646Trpfs*12; VAF 44%],  
RUNX1 [c.776_780delTTAAC, p.Phe259Serfs*339; 
VAF 54%] 
EZH2 [c.1409A>T, p.Gln470Leu; VAF 100%] 
CEBPA [c.441C>A, p.(Tyr147*) VAF 31%] 
&c.678_682dupGCCGC, p.Pro228Argfs*92; VAF 
10%] 
DNMT3A [c.2645G>A, p.Arg882His; VAF 50%] 
SF3B1 [c.2098A>G, p.Lys700Glu; VAF 50%] 
NRAS [c.38G>A, p.Gly13Asp; VAF 11%] 
TET2 [c.1630C>T, p.Arg544*; VAF 5%) & 
[c.2725C>T, p.Gln909*; VAF 94%] 
NF1 [c.6772C>T, p.Arg2258*; VAF 3.1%]. 
46,XY[20]; 
ASXL1 [c.1934dup, p.(Gly646Trpfs*12) VAF 
38%]  
RUNX1 [c.776_780delTTAAC, 
p.Phe259Serfs*339; VAF 40%]  
EZH2 [c.1409A>T, p.Gln470Leu; VAF 100%] 
CEBPA [c.441C>A, p.Tyr147*; VAF 19%] & 
c.678_682dupGCCGC, p.Pro228Argfs*92; VAF 
2.6%] 
DNMT3A [c.2645G>A, p.Arg882His; VAF 35%] 
SF3B1 [c.2098A>G, p.Lys700Glu; VAF 34%] 
NRAS [c.38G>A, p.Gly13Asp; VAF 13%] 
TET2 [c.1630C>T, p.Arg544*; VAF 43%) & 
[c.2725C>T, p.Gln909*; VAF 72%] 
NF1 [c.6772C>T, p.Arg2258*; VAF 18%]. 
#3: Molecular stability with cytogenetic clonal devolution at relapse 
72; F†† de novo; FAB M2 
45, X, -X, der(1)(t(1;13)(q?41;q12),del(5) 
(q1-14q33),del(8)(q13q22), 
del(9)(p12p24),-12,-13,-
16,?add(22)(p10),+3mar[3]/45,sl,i(11)(q10)[5]/44,sl,
add(3)(p24),-7,-8,add(11)(q?24),-16,-
17,18,+4mar[11]/46,XX[1] 
TP53 [c.613T>G, p.(Tyr205Asp); VAF 43%] & 
[c.841G>C, p.Asp281His; VAF 41%]. 
46,XX[20]; 
TP53 [c.613T>G, p.Tyr205Asp; VAF 43%] & 
[c.841G>C, p.Asp281His; VAF 43%]. 
 
#4: Simultaneous clonal evolution and devolution at relapse 
41; M† 
 
sAML 
(post 
MDS) 
46,XY[20] 
KRAS [c.437C>T, p.Ala146Val; VAF 9%] ; 
46,XY[20] 
KRAS negative 
WT1 [c.1105_1106insATCCTGC, 
p.Arg369Hisfs*18; VAF 14%] & [c.1340G>T, p. 
Gly447Val, VAF 12%]  
FLT3-ITD (ratio=0.202). 
#5: Both clonal evolution and devolution at relapse 
65; F† de novo, FAB M1 
46,XX,del(9)(q12q32)[15] 
NPM1 (type D) [c.863_864insCCTG, p.W288fs*12] 
DNMT3A [c.2644C>T, p.Arg882Cys; VAF 43%] 
retrospectively; 
46,XX[20] 
NPM1 (type A) [c.860_863dup, 
p.Trp288Cysfs*12] 
DNMT3A [c.2644C>T, p.Arg882Cys, VAF 43%] 
TET2 [c .3302_3303delTC, p.Leu1101Glnfs*2; 
VAF 34%]. 
#6: Cytogenetic and molecular evolution at relapse 
62; F†† de novo; FAB M1 
46,XX[20]; 
RUNX1 [c.485G>A,p.Arg162Lys; VAF 31%]; 
47,XY,+21[13]/46,XX[7]; 
RUNX1 [c.485G>A, p.Arg162Lys; VAF 32%] & 
[c.780_781insAA, p.Pro261Asnfs*5; VAF 8%]* 
*occurring 5 months after start of relapse therapy. 
AML, acute myeloid leukemia; F., female; FAB, French-American-British classification of AML; M., male; MDS, myelodysplastic syndrome; 
mut/wt., mutated/wild-type; sAML, secondary AML; VAF, variant allele frequency.  
† NGS with Ampliseq EA myeloid panel (Thermo Fisher Scientific, Reinach, Switzerland; 30 genes/hotspots) at diagnosis and relapse. †† NGS 
with Ampliseq EA myeloid panel at diagnosis and Oncomine myeloid panel (Thermo Fisher Scientific, Reinach, Switzerland; 40 
genes/hotspots) at relapse.  
 
autologous stem cell transplantation (ASCT), the patient 
achieved molecular MRD-negative CR1 as assessed by 
PCR/fragment analysis. 4.5 months after ASCT, both 
the NPM1 and FLT3-ITD mutations re-emerged, 
followed by an overt hematologic relapse one month 
later. NGS and cytogenetics revealed no additional 
changes. Salvage therapy (cladribine, cytarabine, and 
idarubicin; CLA-Ida) plus sorafenib resulted in 
morphologic CR2, albeit with the persistence of the 
NPM1 and FLT3-ITD mutations. Matched-related 
myeloablative allogeneic HSCT (11/2017) was 
performed, but molecular MRD persisted at 3 months 
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post-transplant, and sorafenib was once more initiated 
and combined with azacitidine (AZA). At the time of 
this report, the patient remained in molecular CR2, 
meanwhile under continued sorafenib monotherapy. 
 
Patient #2: Molecular and cytogenetic stability at 
relapse after allogeneic transplant. A 63 years old 
male patient developed s-AML following 4 years of 
MDS with a “wait and watch” approach. At the time of 
s-AML, the karyotype was normal, and NGS revealed 
nine mutations in ASXL1, RUNX1, EZH2, CEBPA, 
DNMT3A, SF3B1, NRAS, TET2, and NF1. The patient 
underwent cytarabine/idarubicin induction followed by 
myeloablative allogeneic HSCT in CR1 with the 
molecular persistence of all mutations. Subsequently, 
the patient developed hematologic relapse (d+78 after 
HSCT), demonstrating a normal karyotype and the 
identical mutations seen before. The patient was 
resistant to AZA, donor lymphocyte infusion, and 
gemtuzumab ozogamicin and died 4 months after HSCT 
due to progressive disease.  
 
Patient #3: Molecular stability with cytogenetic 
clonal devolution at relapse. A 72 years old female 
patient was diagnosed with high-risk de novo AML M2 
with a complex multi-clonal karyotype. NGS revealed 
two different mutations in TP53. The patient was 
refractory to standard induction chemotherapy, but 
second-line decitabine (10 cycles) resulted in CR1, and 
NGS documented clearance of the TP53 mutations. Due 
to poor veins, decitabine therapy was switched to AZA. 
Relapse occurred 11.5 months after the achievement of 
CR1; the karyotype was normal, whereas both TP53 
mutations remained detectable. Decitabine treatment 
combined with sorafenib failed to induce any response. 
The patient died one month after relapse detection due 
to progressive disease. 
 
Patient #4: Simultaneous clonal evolution and 
devolution at relapse. Forty-one years old male patient 
presented with s-AML transformed from untreated high-
risk MDS diagnosed three months earlier. Genetic 
analysis revealed a normal karyotype and an isolated 
KRAS mutation by NGS. Induction with two cycles of 
cytarabine and idarubicin resulted in MRD-negative 
CR1. ASCT was performed after 
melphalan/cyclophosphamide HDCT, but hematologic 
relapse occurred 6.4 months following ASCT. In 
contrast to the results obtained in the clone at initial 
diagnosis, the BM at relapse was negative for the KRAS 
mutation but presented with two WT1 mutations and  
FLT3-ITD (ratio=0.202). The patient received CLA-Ida 
salvage therapy and allogeneic HSCT from his HLA-
identical sister. He has been in hematologic and 
molecular CR2 at last follow-up 19 months after relapse.  
 
Patient #5: Both clonal evolution and devolution at 
relapse. A 65 years old female patient presented with de 
novo AML, FAB M1, with a 9q deletion. PCR revealed 
NPM1 mutation type D. The patient received induction 
consisting of cytarabine/idarubicin/laromustin followed 
by busulfan/cyclophosphamide HDCT/ASCT. 
Following a period of long-lasting remission with MRD 
negativity for the NPM1 type D mutation over 8 years, 
the patient showed a 4-log increase of the NPM1 
mutation load detected by qPCR. Still being at 
hematologic CR1, NPM1 re-appearance was detected by 
qPCR as well as NGS but surprisingly identified type A 
instead of type D. Yet, the latter was also confirmed 
retrospectively by NGS at initial diagnosis. In addition, 
a DNMT3A mutation was discovered in the relapse 
sample. Subsequent qPCR assay with a primer designed 
for type A revealed a ratio of 6.285. Six weeks later, BM 
cytomorphology and immunophenotyping revealed up 
to 35% myeloid blasts corresponding to overt AML M2. 
Cytogenetics revealed a normal karyotype, with a lack 
of the 9q deletion documented at first diagnosis. We 
have previously described this switch of NPM1 types 
(from type D to type A).9 The DNMT3A mutation 
identified at relapse was retrospectively detected in 
stored material from initial diagnosis. The patient 
underwent salvage chemotherapy, followed by 
busulfan/melphalan HDCT/ASCT. Subsequently, 
maintenance therapy with AZA was started resulting in 
NPM1 MRD-negative CR2 ongoing 22 months after 
diagnosis of relapse. Finally, a TET2 mutation was also 
found retrospectively with a variant allele frequency 
(VAF) of 43% in addition to DNMT3A (47% VAF) in 
the autologous stem cell harvest preceding the 2nd 
ASCT. TET2 and DNMT3A mutations persisted at last 
follow-up (34%/43% VAF) despite NPM1 type A 
mutation clearance suggesting an interpretation of 
clonal hematopoiesis of indeterminate potential (CHIP). 
 
Patient #6: Cytogenetic and molecular evolution at 
relapse. A 62-year-old female patient came to 
observation with de novo AML, FAB M1, and a 
peripheral blast count of 55%. The NGS panel revealed 
a RUNX1 mutation with a VAF of 31%, and 
cytogenetics showed a normal karyotype. The patient 
received two cycles of induction (daunorubicin, 
cytarabine), resulting in CR1 and MRD-negativity for 
the RUNX1 mutation by NGS. This was followed by 
HDCT consisting of busulfan/melphalan and ASCT 
since the patient declined allogeneic transplantation. 
Hematological regeneration was heavily delayed. Five 
months after ASCT, the patient developed hematologic 
relapse. At this stage, BM presented a clonal cytogenetic 
evolution with a novel gain of chromosome 21 in 
addition to the re-emergence of the RUNX1 mutation 
that had already been present at the initial diagnosis. 
Relapse therapy was initiated by decitabine after the 
patient declined intensive re-induction treatment. Blasts, 
however, persisted, which was 5 months later 
 
  www.mjhid.org Mediterr J Hematol Infect Dis 2020; 12; e202068                                                         Pag. 4 / 5 
 
accompanied by an additional, i.e., second, RUNX1 
mutation suggesting further molecular clonal evolution. 
Palliative therapy was administered by decitabine (9 
cycles), then with low-dose cytarabine with glasdegib 
(hedgehog pathway inhibitor), and finally, sorafenib. 
The patient succumbed to refractory disease one month 
after the sorafenib start and 15 months after the first 
relapse. 
 
Conclusions. As demonstrated by our case series, each 
patient may present with an individual genetic 
composition at relapse of AML. Compared to the initial 
diagnosis, this may comprise clonal stability, evolution, 
or devolution alone or in combination both at the 
molecular and/or cytogenetic level. Consequently, the 
genetic characterization during relapse may identify 
novel lesions treatable by targeted therapies or may open 
new pathways for bridging strategies towards allogeneic 
HSCT. This can be illustrated, for example, by FLT3 
mutations, which are emerging in around 10% of AML 
patients at relapse 10, and may provide an option for 
specific FLT3 inhibitor treatment, such as midostaurin, 
gilteritinib or others.11,12 Similarly, both IDH1 
(ivosidenib) and IDH2 (enasidenib) inhibitors were 
recently approved in AML with the respective 
mutations.13,14 Knowledge of relapse genetics may 
imply consequences also for prognosis. Adverse 
prognostic markers, such as TP53 mutations emerging 
at relapse, may allow timely initiation of donor search 
for subsequent allogeneic HSCT. Accordingly, the 
development of distinct diagnostics and therapeutic 
algorithms for clonal stability, evolution, and 
devolution, as well as defining of “founder” mutations 
in relapsed AML settings may further ease the 
management of such patients. Anticipating anti-relapse 
treatment with targeted agents, the determination of 
mutant allele frequencies is of high importance as these 
provide a sensitive diagnostic tool to assess response on 
the molecular level and predict progression over time. In 
conclusion, NGS may be discussed for all patients at 
AML relapse. Due to recent improvements in treatment 
options and an increasing understanding of the 
molecular drivers of AML, therapy in the relapse 
situation becomes more and more individualized, and, 
consequently, NGS will gain increasing importance in 
this scenario.  
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